Ralph Klose1, Caroline Berger2, Iris Moll1, M Gordian Adam2, Frank Schwarz3, Kerstin Mohr3, Hellmut G Augustin4, Andreas Fischer5. 1. Vascular Signaling and Cancer (A270), German Cancer Research Center (DKFZ-ZMBH Alliance), Heidelberg D-69120, Germany. 2. Vascular Signaling and Cancer (A270), German Cancer Research Center (DKFZ-ZMBH Alliance), Heidelberg D-69120, Germany Vascular Biology and Tumor Angiogenesis, Medical Faculty Mannheim (CBTM), Heidelberg University, Mannheim D-68167, Germany. 3. Genomics and Proteomics Core Facilities, German Cancer Research Center, Heidelberg D-69120, Germany. 4. Vascular Biology and Tumor Angiogenesis, Medical Faculty Mannheim (CBTM), Heidelberg University, Mannheim D-68167, Germany Vascular Oncology and Metastasis (A190), German Cancer Research Center (DKFZ-ZMBH Alliance), Heidelberg D-69120, Germany. 5. Vascular Signaling and Cancer (A270), German Cancer Research Center (DKFZ-ZMBH Alliance), Heidelberg D-69120, Germany Vascular Biology and Tumor Angiogenesis, Medical Faculty Mannheim (CBTM), Heidelberg University, Mannheim D-68167, Germany Department of Medicine I and Clinical Chemistry, Heidelberg University, Heidelberg D-69120, Germany a.fischer@dkfz-heidelberg.de.
Abstract
AIMS: Notch signalling is essential for blood vessel formation. During angiogenesis, the Notch ligand DLL4 on the leading tip cell activates Notch receptors on the adjacent stalk cells. DLL4-Notch signalling is impaired by the Notch ligand JAG1 in endothelial cells. The Delta/Serrate/Lag2 (DSL) domain of the Notch ligands binds to the EGF-like repeats 11-13 of the Notch receptor. This study aimed to elucidate how soluble proteins containing these short domains interfere with Notch signalling during angiogenesis. METHODS AND RESULTS: Adenoviral vectors were generated to express the DSL domains of DLL1, DLL4, JAG1, and the Notch1 EGF-like repeats 11-13 fused to immunoglobulin-G heavy chain. These soluble ligand peptides inhibited Notch signalling in endothelial cells and this caused hyperbranching in cellular angiogenesis assays and in the neonatal mouse retina. The soluble Notch receptor peptides bound stronger to JAG1 than DLL4 ligands, resulting in increased signalling activity. This led to impaired tip cell formation and less vessel sprouting in the retina. CONCLUSION: The minimal binding domains of Notch ligands are sufficient to interfere with Notch signalling. The corresponding soluble Notch1 EGF11-13 peptide binds stronger to inhibitory Notch ligands and thereby promotes Notch signalling in endothelial cells. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Notch signalling is essential for blood vessel formation. During angiogenesis, the Notch ligand DLL4 on the leading tip cell activates Notch receptors on the adjacent stalk cells. DLL4-Notch signalling is impaired by the Notch ligand JAG1 in endothelial cells. The Delta/Serrate/Lag2 (DSL) domain of the Notch ligands binds to the EGF-like repeats 11-13 of the Notch receptor. This study aimed to elucidate how soluble proteins containing these short domains interfere with Notch signalling during angiogenesis. METHODS AND RESULTS: Adenoviral vectors were generated to express the DSL domains of DLL1, DLL4, JAG1, and the Notch1 EGF-like repeats 11-13 fused to immunoglobulin-G heavy chain. These soluble ligand peptides inhibited Notch signalling in endothelial cells and this caused hyperbranching in cellular angiogenesis assays and in the neonatal mouse retina. The soluble Notch receptor peptides bound stronger to JAG1 than DLL4 ligands, resulting in increased signalling activity. This led to impaired tip cell formation and less vessel sprouting in the retina. CONCLUSION: The minimal binding domains of Notch ligands are sufficient to interfere with Notch signalling. The corresponding soluble Notch1 EGF11-13 peptide binds stronger to inhibitory Notch ligands and thereby promotes Notch signalling in endothelial cells. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Yoon Mee Yang; Mazen Noureddin; Cheng Liu; Koichiro Ohashi; So Yeon Kim; Divya Ramnath; Elizabeth E Powell; Matthew J Sweet; Yoon Seok Roh; I-Fang Hsin; Nan Deng; Zhenqiu Liu; Jiurong Liang; Edward Mena; Daniel Shouhed; Robert F Schwabe; Dianhua Jiang; Shelly C Lu; Paul W Noble; Ekihiro Seki Journal: Sci Transl Med Date: 2019-06-12 Impact factor: 17.956
Authors: Gabriela D'Amico; Isabelle Fernandez; Jesús Gómez-Escudero; Hyojin Kim; Eleni Maniati; Muhammad Syahmi Azman; Faraz K Mardakheh; Bryan Serrels; Alan Serrels; Maddy Parsons; Anthony Squire; Graeme M Birdsey; Anna M Randi; Alfonso Bolado-Carrancio; Rathi Gangeswaran; Louise E Reynolds; Natalia Bodrug; Yaohe Wang; Jun Wang; Pascal Meier; Kairbaan M Hodivala-Dilke Journal: Development Date: 2022-07-12 Impact factor: 6.862
Authors: Edit Gara; Eleonora Zucchelli; Annamária Nemes; Zoltán Jakus; Kitti Ajtay; Éva Kemecsei; Gábor Kiszler; Nikolett Hegedűs; Krisztián Szigeti; Iván Földes; Kristóf Árvai; János Kósa; Kraszimir Kolev; Erzsébet Komorowicz; Parasuraman Padmanabhan; Pál Maurovich-Horvat; Edit Dósa; György Várady; Miklós Pólos; István Hartyánszky; Sian E Harding; Béla Merkely; Domokos Máthé; Gábor Szabó; Tamás Radovits; Gábor Földes Journal: Theranostics Date: 2022-06-06 Impact factor: 11.600